Rexahn Pharma (RNN) Will Update on Supinoxin Phase, RX-3117 Phase 1b/2a at ESMO 2016

October 4, 2016 9:01 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) announced it will present the preliminary Phase Ib/IIa efficacy data for RX-3117 in metastatic pancreatic cancer and an update on the Supinoxin Phase I clinical trial at the 2016 European Society for Medical Oncology (ESMO) Congress, which will take place October 7th – 11th in Copenhagen, Denmark.

Poster sessions:

RX-3117, an oral antimetabolite to treat advanced solid tumors (ST): Phase 1 and ongoing phase 2a results. D. Rasco (San Antonio, United States of America), C. Peterson (Rockville, United States of America), R. Mazhari (Rockville, United States of America), E. Benaim (Rockville, United States of America), and J. Merchan (Miami, United States of America) (Abstract 396P)

Date/time: Monday October 10, 2016, 13:00 – 14:00 (CEST)

Location: Hall E

Phase 1/2a study of RX-5902 in advanced solid tumors (ST): An orally bioavailable inhibitor of phosphorylated P68 and modulator of β-catenin nuclear translocation. S. Eckhardt (Denver, United States of America) , W. L. Gluck (Greenville, United States of America), M. Gutierrez (Hackensack, United States of America), C. Peterson (Rockville, United States of America), R. Mazhari (Rockville, United States of America), and E. Benaim (Rockville, United States of America) (Abstract 385P)

Date/time: Monday October 10, 2016, 13:00 – 14:00 (CEST)

Location: Hall E



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment